George Diggs, MD
Addiction Psychiatry · Lafayette, LANPI 1699700880
Payments from drug & device makers
Across 423 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$913
- Otsuka America Pharmaceutical, Inc.$562
- Johnson & Johnson$557
- plus $1K from 12 others
What the payments were for
- Food & beverage$6,79097%
- Education$2233%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 131 | $1,399 |
| Teva Pharmaceuticals USA, Inc. | 46 | $1,184 |
| Neurocrine Biosciences, Inc. | 57 | $1,157 |
| Alkermes, Inc. | 51 | $913 |
| Otsuka America Pharmaceutical, Inc. | 30 | $562 |
| Johnson & Johnson | 33 | $557 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $398 |
| E.r. Squibb & Sons, L.L.C. | 15 | $256 |
| Vanda Pharmaceuticals Inc. | 10 | $236 |
| Indivior Inc. | 4 | $96 |
| Lundbeck LLC | 3 | $52 |
| Philips North America LLC | 1 | $45 |
| Braeburn Inc. | 2 | $42 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Acadia Pharmaceuticals Inc | 2 | $26 |
| Noven Therapeutics, LLC | 1 | $20 |
| Luye Pharma (USA) Ltd. | 1 | $17 |
| Bioxcel Therapeutics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$123
How this compares
Too few addiction psychiatry providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 30 | $245,003 |
| Invega SustennaPaliperidone Palmitate | 85 | $237,509 |
| VraylarCariprazine Hcl | 106 | $156,742 |
| CaplytaLumateperone Tosylate | 61 | $103,653 |
| AustedoDeutetrabenazine | 25 | $98,516 |
| RexultiBrexpiprazole | 47 | $75,648 |
| LybalviOlanzapine/Samidorphan Malate | 37 | $63,414 |
| Abilify MaintenaAripiprazole | 21 | $53,967 |
| BelsomraSuvorexant | 69 | $30,296 |
| TrintellixVortioxetine Hydrobromide | 30 | $18,903 |
| Lurasidone Hcl | 65 | $17,105 |
| Clozapine | 442 | $15,032 |
| VyvanseLisdexamfetamine Dimesylate | 19 | $7,942 |
| Quetiapine Fumarate | 394 | $7,856 |
| Ramelteon | 69 | $6,825 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,157 | $245,00330 claims |
| Johnson & JohnsonInvega Sustenna | $557 | $237,50985 claims |
| AbbVieVraylar | $1,399 | $156,742106 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $562 | $129,61568 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $398 | $103,65361 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Loxapine | $1,184 | $99,97366 claims |
| Alkermes, Inc.Lybalvi | $913 | $63,41437 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction psychiatry providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other addiction psychiatry in Lafayette
- Gregory CaudillNew Orleans$9K
- Olufemi OgundejiShreveport$8K
- Tawfik Mukhtar-BenghoziAlexandria$2K
- Tiffany ArnoldMetairie$423
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.